Transanal excision with adjuvant therapy for pT1N0 rectal tumors with high-risk features offers equivalent survival to radical resection: A National Cancer Database analysis.
Katherine A HrebinkoKatherine M ReitzMaryam K MohammedIbrahim NassourAndrew R WatsonKellie E CunninghamDavid S MedichJames P CelebrezzeJennifer M Holder-MurrayPublished in: Journal of surgical oncology (2021)
This is the largest study to demonstrate equivalent 5-year OS between TAXa and RR for T1N0 rectal cancer with high-risk features. These findings may guide the development of prospective, randomized trials and influence changes in practice recommendations for early-stage rectal cancer.